Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir

C Petit-Bibal1, A Rothenbuhler1, P Lucchini1

  • 1AP-HP, Department of Pediatric Endocrinology, Bicêtre Hospital, Paris Sud University, Pôle I3E, 94275, Le Kremlin Bicetre, France.

Pediatric Diabetes
|June 4, 2014
PubMed

Insights

Free-mixing aspart and detemir insulins (ADIM) significantly reduced hypoglycemia in young children with type 1 diabetes compared to fixed-ratio premixed insulin (ANIM). This flexible approach improved diabetes management by lowering severe and symptomatic hypoglycemic events.

Area of Science:

  • Endocrinology
  • Pediatric Diabetes Management
  • Pharmacology

Background:

  • Type 1 diabetes (T1D) in children requires careful insulin management.
  • Twice-daily insulin injections are common for pediatric T1D.
  • Premixed insulins offer convenience but may lack flexibility.

Purpose of the Study:

  • To compare the effectiveness of a free-mix of aspart and detemir insulins (ADIM) versus a fixed-ratio premixed insulin (aspart/NPH, ANIM).
  • To evaluate the impact on hypoglycemia and glycemic control in young children with T1D.
  • To assess the benefits of personalized insulin preparations over fixed mixtures.

Main Methods:

  • An open-label, randomized trial involving 82 children with T1D.
  • Patients initially received ANIM for one year of optimization.
  • Subsequent randomization to either continued ANIM or ADIM for a second year.

Main Results:

  • ADIM significantly reduced symptomatic hypoglycemia by approximately twofold (p < 0.001).
  • ADIM decreased severe hypoglycemia by 7-10 fold (p = 0.04).
  • Mean HbA1c levels were comparable between ADIM (7.9%) and ANIM (8.2%) groups.

Conclusions:

  • Free-mixing aspart and detemir insulins effectively reduces hypoglycemia in pediatric T1D.
  • ADIM offers a safer alternative to fixed-ratio premixed insulins in young children.
  • Personalized insulin regimens may improve safety without compromising glycemic control.
Abstract

Related Concept Videos

Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
29
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.4K
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
21
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K